FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 139 filers reported holding FIVE PRIME THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 3.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $510,000 | +117.0% | 30,000 | -40.0% | 0.05% | +100.0% |
| Q3 2020 | $235,000 | -23.0% | 50,000 | 0.0% | 0.02% | -30.6% |
| Q2 2020 | $305,000 | +167.5% | 50,000 | 0.0% | 0.04% | +111.8% |
| Q1 2020 | $114,000 | -17.4% | 50,000 | +66.7% | 0.02% | +6.2% |
| Q4 2019 | $138,000 | +19.0% | 30,000 | 0.0% | 0.02% | +6.7% |
| Q3 2019 | $116,000 | -35.9% | 30,000 | 0.0% | 0.02% | -34.8% |
| Q2 2019 | $181,000 | -55.0% | 30,000 | 0.0% | 0.02% | -58.9% |
| Q1 2019 | $402,000 | +332.3% | 30,000 | +200.0% | 0.06% | +273.3% |
| Q4 2018 | $93,000 | -33.1% | 10,000 | 0.0% | 0.02% | -21.1% |
| Q3 2018 | $139,000 | -12.0% | 10,000 | 0.0% | 0.02% | -17.4% |
| Q2 2018 | $158,000 | -8.1% | 10,000 | 0.0% | 0.02% | -11.5% |
| Q1 2018 | $172,000 | -68.6% | 10,000 | -60.0% | 0.03% | -68.3% |
| Q4 2017 | $548,000 | +118.3% | 25,000 | +400.0% | 0.08% | +86.4% |
| Q4 2016 | $251,000 | -4.2% | 5,000 | 0.0% | 0.04% | -8.3% |
| Q3 2016 | $262,000 | – | 5,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |